nach oben

Erschienen in:

06.02.2019 | Original Article

Adherence and quality of life in women with breast cancer being treated with oral hormone therapy

verfasst von: Rebeca Stahlschmidt, Amanda Canato Ferracini, Cinthia Madeira de Souza, Luana Moreira de Medeiros, Cassia Raquel Teatin Juliato, Priscila Gava Mazzola

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate adherence to oral hormone therapy (HT) and which factors impact in incomplete adherence and quality of life.

Methods

This was a cross-sectional study. Setting: Women’s Hospital Prof. Dr. José Aristodemo Pinotti. Participants: women with breast cancer under treatment with oral HT. Main outcome measures: interview and performed an adherence questionnaire (Morisky–Green) and two questionnaires of quality of life (EORTC-QLQ30/BR23). The interviews were done once in a 5-month period.

Results

Fifty-eight women were interviewed: 42 under treatment with tamoxifen (TX) and 16 under treatment with aromatase inhibitor (AI). Twenty-six women (44%) showed high adherence to the treatment, 31 (54%) medium adherence, and 1 (2%) low adherence. Statistical analysis showed a relation between incomplete adherence and systemic therapy side effects as well as higher stages of disease, with no difference between the two drugs. When treatments were compared, this study showed treatment with AI presented less breast symptoms and better role functioning. Quality of life score was high, compared to the reference value.

Conclusions

A low percentage of women with breast cancer were highly adherent to HT treatment. Low/medium adherence was associated with higher stages of disease and systemic side effects. Quality of life had high scores, with better role function and less breast symptoms in women being treated with an AI.

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice guideline focused update. J Clin Oncol 32(21):2255–2269. https://doi.org/10.1200/JCO.2013.54.2258 CrossRefPubMedPubMedCentral

Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339(22):1609–1618. https://doi.org/10.1056/NEJM199811263392207 CrossRefPubMed

Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM (2002) An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 95(9):2006–2016. https://doi.org/10.1002/cncr.10908 CrossRefPubMed

Burich R, DeGregorio M (2011) Current treatment options for vulvovaginal atrophy. Expert Rev Obstet Gynecol 6(2):141–151. https://doi.org/10.1586/eog.11.3 CrossRef

Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, investigators I-I (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922):1041–1048. https://doi.org/10.1016/S0140-6736(13)62292-8 CrossRefPubMed

Findlay M, von Minckwitz G, Wardley A (2008) Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 19(2):212–222. https://doi.org/10.1093/annonc/mdm285 CrossRefPubMed

Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H (2001) Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist 6(Suppl 4):12–16CrossRefPubMed

Bedell CH (2003) A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs 7(6 Suppl):5–9. https://doi.org/10.1188/03.CJON.S6.5-9 CrossRefPubMed

Hartigan K (2003) Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs 7(6 Suppl):21–24. https://doi.org/10.1188/03.CJON.S6.21-24 CrossRefPubMed

10.

Schott S, Schneeweiss A, Reinhardt J, Bruckner T, Domschke C, Sohn C, Eichbaum MH (2011) Acceptance of oral chemotherapy in breast cancer patients—a survey study. BMC Cancer 11:129. https://doi.org/10.1186/1471-2407-11-129 CrossRefPubMedPubMedCentral

11.

Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478. https://doi.org/10.1007/s10549-012-2114-5 CrossRefPubMedPubMedCentral

12.

Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, Lennes I, Temel JS, Safren SA, Pirl WF (2016) A systematic review of adherence to oral antineoplastic therapies. Oncologist 21(3):354–376. https://doi.org/10.1634/theoncologist.2015-0405 CrossRefPubMedPubMedCentral

13.

Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497. https://doi.org/10.1056/NEJMra050100 CrossRefPubMed

14.

Kilickap S, Hayran M, Cakir B, Cilingiroglu N, Erman M, Buyukdamgaci G, Ozisik Y (2013) Effect of endocrine therapy on quality of life and cognitive functions in patients with breast cancer. Breast Care (Basel) 8(2):128–132. https://doi.org/10.1159/000350780 CrossRef

15.

van Nes JG, Fontein DB, Hille ET, Voskuil DW, van Leeuwen FE, de Haes JC, Putter H, Seynaeve C, Nortier JW, van de Velde CJ (2012) Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat 134(1):267–276CrossRefPubMedPubMedCentral

16.

The Development of the World Health Organization Quality of Life Assessment Instrument (the WHOQOL) (1994). In: Orley J, Kuyken W (eds) Quality of life assessment: international perspectives: Proceedings of the Joint-Meeting Organized by the World Health Organization and the Fondation IPSEN in Paris, July 2–3, 1993. Springer Berlin Heidelberg, Berlin, Heidelberg, pp 41–57. https://doi.org/10.1007/978-3-642-79123-9_4

17.

Cipolle RJ, Strand L, Morley P (2004) Pharmaceutical care practice: the clinician’s guide. 2nd edn. Mc Graw Hill, New York

18.

Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24(1):67–74CrossRefPubMed

19.

Michels FA, Latorre MR, Maciel MS (2013) Validity, reliability and understanding of the EORTC-C30 and EORTC-BR23, quality of life questionnaires specific for breast cancer. Rev Bras Epidemiol 16(2):352–363. https://doi.org/10.1590/S1415-790X2013000200011 CrossRefPubMed

20.

Conover WJ (1999) Practical nonparametric statistics. 3rd edn. Wiley, New York

21.

Fleiss JL (1981) Statistical methods for rates and proportions. 2nd edition edn. Wiley, New York

22.

Agresti A, Finlay B (1986) Statistical methods for the social sciences. Dellen Publishing Company, San Francisco

23.

Stevens J (1992) Applied multivariate statistics for the social sciences. 2nd edn. Lawrence Erlbaum Associates, New Jersey

24.

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R, (EBCTCG) EBCTCG (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. https://doi.org/10.1016/S0140-6736(11)60993-8 CrossRefPubMed

25.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, Group AT (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62. https://doi.org/10.1016/S0140-6736(04)17666-6 CrossRefPubMed

26.

van de Water W, Bastiaannet E, Hille ET, Meershoek-Klein Kranenbarg EM, Putter H, Seynaeve CM, Paridaens R, de Craen AJ, Westendorp RG, Liefers GJ, van de Velde CJ (2012) Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. Oncologist 17(1):55–63. https://doi.org/10.1634/theoncologist.2011-0037 CrossRefPubMed

27.

Banning M (2012) Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl) 21(1):10–19. https://doi.org/10.1111/j.1365-2354.2011.01295.x CrossRef

28.

Kuba S, Maeda S, Matsumoto M, Yamanouchi K, Yano H, Morita M, Sakimura C, Hatachi T, Tokai Y, Takatsuki M, Fujioka H, Hayashida N, Nagayasu T, Eguchi S (2017) Adherence to adjuvant endocrine therapy in women with breast cancer: a prospective observational study in Japanese women. Clin Breast Cancer 18:150–156. https://doi.org/10.1016/j.clbc.2017.12.003 CrossRefPubMed

29.

Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537. https://doi.org/10.1007/s10549-010-1132-4 CrossRefPubMed

30.

Sawesi S, Carpenter JS, Jones J (2014) Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review. Clin J Oncol Nurs 18(3):E50–E57. https://doi.org/10.1188/14.CJON.E50-E57 CrossRefPubMed

31.

Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Group obotEQoL (2008) EORTC QLQ-C30 reference values manual

32.

Juliato PT, Rodrigues AT, Stahlschmidt R, Juliato CR, Mazzola PG (2017) Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen? Climacteric 20(1):62–66. https://doi.org/10.1080/13697137.2016.1258396 CrossRefPubMed

Titel: Adherence and quality of life in women with breast cancer being treated with oral hormone therapy
verfasst von: Rebeca Stahlschmidt
Amanda Canato Ferracini
Cinthia Madeira de Souza
Luana Moreira de Medeiros
Cassia Raquel Teatin Juliato
Priscila Gava Mazzola
Publikationsdatum: 06.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 10/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04671-x

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Adherence and quality of life in women with breast cancer being treated with oral hormone therapy